Vimarsana
Biggest News Aggregation in the World

Chief Discovery News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chief Discovery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chief Discovery Today - Breaking & Trending Today

Baystreet.ca - Biotech's Developments in Race Against Rising Cancer Rates Revealed - Vimarsana News

Baystreet.ca - Biotech's Developments in Race Against Rising Cancer Rates Revealed

USA News Group – According to a “highly troubling” new study, the rising number of cancer cases in young people is being attributed to “accelerated aging.” Further alarm is being spread by the United Nations, whose health ...

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 - Vimarsana News

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

/PRNewswire/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging."...

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 - Vimarsana News

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by the United Nations, whose health authorities are predicting global cancer...

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate - Vimarsana News

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer models Initiating IND-enabling studies with goal...

Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Olema Pharmaceuticals (NASDAQ:OLMA) - Vimarsana News

Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Olema Pharmaceuticals (NASDAQ:OLMA)

SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and